Funded Startups in Newton
Rounds listed for Newton span 2020-04-20 (Zikani Therapeutics) through 2025-10-18 (Gelmedix), with the most recent entry in late 2025.
Rounds listed for Newton span 2020-04-20 (Zikani Therapeutics) through 2025-10-18 (Gelmedix), with the most recent entry in late 2025. The largest disclosed amount is DUST Identity’s $40M Series B on 2023-12-05; it sits well above the next-largest disclosed rounds (e.g., Karyopharm Therapeutics at $165M on 2022-12-05 is the real maximum disclosed), while several other large figures cluster in the tens of millions such as First Help Financial’s $60M debt financing on 2021-11-17 and Seven Hills’ $28M on 2023-07-18. Sector concentration is also visible: biotechnology appears in multiple entries (e.g., Gelmedix 2025-10-18, MelliCell 2024-10-24, Inflammasome Therapeutics 2023-08-14, Karyopharm Therapeutics 2022-12-05, Abcuro 2021-01-07, Zikani Therapeutics 2020-04-20), while health care is another recurring cluster (Alleviate $4M on 2023-02-15, PaxeraHealth AI 2022-12-12 is categorized as AI, plus multiple “undisclosed” health-care rows like HouseWorks 2023-01-12 and Family Access Of Newton 2023-06-21). Stage disclosure is uneven: 10 of 28 entries are “undisclosed,” and 6 of 28 are labeled “Series Unknown.”
Most recent rounds
28 shownRelated listings
Frequently asked
Which Newton round is the clear outlier by disclosed size, and what does the rest look like?
The largest disclosed amount is Karyopharm Therapeutics at $165M on 2022-12-05, which dwarfs the next-largest disclosed figures like First Help Financial’s $60M debt financing (2021-11-17) and DUST Identity’s $40M Series B (2023-12-05). Several other disclosed rounds fall into lower single-digit millions or the $20M–$40M band, but none approach the $165M scale.
Do the Newton rounds cluster in time, or are they evenly spread across years?
They’re not concentrated into a single quarter: the shown set starts at 2020-04-20 (Zikani Therapeutics) and includes many exits across 2021–2024, with notable dense activity around late 2022 (e.g., Karyopharm Therapeutics $165M on 2022-12-05; PaxeraHealth “Series A” undisclosed on 2022-12-12) and mid-2023 (e.g., Inflammasome Therapeutics $3M on 2023-08-14; DUST Identity $40M on 2023-12-05). The timeline extends to 2025-10-18 with Gelmedix $400K.
Are certain sectors over-represented in this Newton sample?
Biotechnology shows up repeatedly across the period, including Gelmedix (2025-10-18, $400K), MelliCell (2024-10-24, undisclosed), Inflammasome Therapeutics (2023-08-14, $3M), Karyopharm Therapeutics (2022-12-05, $165M), Abcuro (2021-01-07, $42M), and Zikani Therapeutics (2020-04-20, $8M). Health care is also frequent (e.g., Alleviate $4M on 2023-02-15, Agile Devices $1M on 2022-12-13, Meetcaregivers $1M on 2021-08-19), often paired with “undisclosed” amounts.
How much of the list has unclear funding stage or amount disclosures?
Stage disclosure is incomplete: 10 of 28 rows have the amount as “undisclosed,” and 6 of 28 are labeled “Series Unknown” (e.g., MelliCell 2024-10-24, undisclosed; Inflammasome Therapeutics 2023-08-14, $3M but labeled “Series Unknown”; HouseWorks 2023-01-12, undisclosed). This means size-based comparisons skew toward the subset with explicit dollar amounts.
Which companies set the recent edge of the dataset, and how big are they compared to older rounds?
The most recent dated entry is Gelmedix on 2025-10-18 with a $400K Seed. Just behind it, ShipIn closed 2025-10-08 with $11M, which is still far smaller than earlier top-end disclosed rounds like Karyopharm Therapeutics $165M (2022-12-05) and First Help Financial $60M (2021-11-17).
Are there any Newton geography inconsistencies or is the dataset mostly single-city Newton?
Most entries list Newton, Massachusetts (e.g., ShipIn 2025-10-08; DUST Identity 2023-12-05), with a single “Newton, United States” label for Gelmedix (2025-10-18) and one entry outside Massachusetts: Sussex County Community College in Newton, New Jersey (2023-07-13, $10K).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.